3rd Circ.: Biotech Must Pay Royalties Despite Expired Patents

By Hannah Albarazi · September 3, 2024, 7:00 PM EDT

A cancer drug biotechnology company must pay royalties to a research firm despite the expiration of the applicable patents, a Third Circuit panel ruled in a precedential decision Tuesday, concluding that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Decision

Case Information

Case Title

Ares Trading SA v. Dyax Corp

Case Number

Court

Appellate - 3rd Circuit

Nature of Suit

4190 Other Contract Actions

Date Filed

March 24, 2023

Recent Articles By Hannah

November 20, 2024
Hospital's Med Mal Win Axed By Mich. Appeals Panel
November 15, 2024
Abbott Inks $8M Deal With Healthcare Fraudster In TM Suit
November 04, 2024
DOD Trans Healthcare Denial Discriminates, Judge Rules
October 29, 2024
Retired Fed. Circ. Judge Backs Invisalign In Monopoly Cases
October 11, 2024
Apple Watch Patents Dodge Ax As Masimo Jury Trial Nears
October 01, 2024
From AI To Enviro: The Top Biz Bills Calif. Gov. Inked Into Law
September 27, 2024
Why Many Drugs Remain Pricey 40 Years After Hatch-Waxman
September 11, 2024
Top Calif. Biz Bills Sitting On Gov. Newsom's Desk
August 20, 2024
Ala. AG Can't Prosecute Aiding Abortion Travel, DOJ Says
August 13, 2024
Are 'Public Advantage' Laws Driving Up Healthcare Costs?